 | NnBU (NNBU)ICO NnBU is a revolutionary healthcare device that provides postnatal treatments after caesarean-section deliveries backed by blockchain technology IMPORTANT: By investing in this business you agree to ourDisclaimer. All information including our rating, is provided merely for informational purposes. CryptoTotem does not provide investment advice. |
Overview
|
OpenWhat is NnBU
NnBU device, situated in hospitals and clinics, used straight after the baby is born, seeks to reproduce part of these positive stresses in a controlled manner. This gives the baby the benefits of a natural birth, even though they were born by Caesarean-section.
The device applies a controlled pressure to the baby in different sections of the torso for a predetermined period while also holding the baby in a warm, comfortable environment. Also, because most C-section babies are asleep when delivered, the NnBU device also focuses lighton the babys fontanel in order to create a comfortable waking process for the newborn baby.
DetailsPre-sales: Mar 19, 2018 - Mar 25, 2018Public sales: Mar 26, 2018 - Apr 25, 2018 Pre-sale token supply: 15000000 Token supply: 37500000 Soft cap: 10,686,400USD Hard cap: 18,639,000USD LegalRegistration country: CyprusRegistration year: 2017 Office address: 30 Tempon, 2408 Engomi,Nicosia, Cyprus | Token infoTicker: NNBUType: Security Token standard: ERC-20 Dividends: Token holders will get a percentage of revenues. Token price in USD: 1 Token = 0.397600 USD Accepted currencies: ETH Token distribution: 75% - Token sale 25% - Pre-sale Funds allocation: 62% - Research and Development; Capital Expenditure for the Assembly and Testing facility; 12% - Cash Reserve 12% - Other operating expenses during the development period 7% - Negative cash flow; Investors pay-out during the first year of commercial operations EUR 1,115,000 7% - Market entry costs |
NnBU Roadmap
Development of the medical device in cooperation with Fraunhofer IPA;
Device certification by DMTpe GmbH;
Global intellectual property protection;
Development of the medical device in cooperation with Fraunhofer IPA;
Device certification by DMTpe GmbH;
Global intellectual property protection;
Germany, Austria & Switzerland (DACH) market entry;
Investors pay-out in Y1;
France & Benelux market entry;
Brasil & Argentina market entry;
Mexico market entry;
US and Canada market entry; Investors pay-out in Y2;
Other European countries (UK, Italy, Portugal, Spain, Poland, Hungary, Slovakia, Czech Republic) market entry;
Turkey and Egypt market entry.
Investors pay-out in Y3;
China, India and Indonesia market entry.
Investors pay-out in Y4;
Investors pay-out in Y5;
Project team
Social media
